Additionally, genetic alterations affecting the function of the p53 pathway, such as CDKN2A/ARF deletion or MDM2/MDM4 amplification, could be present in ~85% of all GBM patients (16) and had similar effects on the pro-survival effect of VPA treatment. Here, CDKN2A is linked to glioblastoma.